Cytochrome P4502C9 activity in end-stage renal disease
Albert W. Dreisbach MD
Sections of Nephrology and Clinical Pharmacology, Departments of Medicine, Pathology, and Pharmacology, Tulane University School of Medicine, New Orleans, La, USA
Search for more papers by this authorShanker Japa PhD
Sections of Nephrology and Clinical Pharmacology, Departments of Medicine, Pathology, and Pharmacology, Tulane University School of Medicine, New Orleans, La, USA
Search for more papers by this authorAster B. Gebrekal BS
Sections of Nephrology and Clinical Pharmacology, Departments of Medicine, Pathology, and Pharmacology, Tulane University School of Medicine, New Orleans, La, USA
Search for more papers by this authorSarah E. Mowry BS
Sections of Nephrology and Clinical Pharmacology, Departments of Medicine, Pathology, and Pharmacology, Tulane University School of Medicine, New Orleans, La, USA
Search for more papers by this authorJuan J. L. Lertora MD, PhD
Sections of Nephrology and Clinical Pharmacology, Departments of Medicine, Pathology, and Pharmacology, Tulane University School of Medicine, New Orleans, La, USA
Search for more papers by this authorBurde L. Kamath PhD
Department of Pharmacokinetics, Xavier University College of Pharmacy, New Orleans, La, USA
Search for more papers by this authorAllan E. Rettie PhD
Department of Medicinal Chemistry, University of Washington School of Pharmacy, Seattle, Wash, USA
Search for more papers by this authorAlbert W. Dreisbach MD
Sections of Nephrology and Clinical Pharmacology, Departments of Medicine, Pathology, and Pharmacology, Tulane University School of Medicine, New Orleans, La, USA
Search for more papers by this authorShanker Japa PhD
Sections of Nephrology and Clinical Pharmacology, Departments of Medicine, Pathology, and Pharmacology, Tulane University School of Medicine, New Orleans, La, USA
Search for more papers by this authorAster B. Gebrekal BS
Sections of Nephrology and Clinical Pharmacology, Departments of Medicine, Pathology, and Pharmacology, Tulane University School of Medicine, New Orleans, La, USA
Search for more papers by this authorSarah E. Mowry BS
Sections of Nephrology and Clinical Pharmacology, Departments of Medicine, Pathology, and Pharmacology, Tulane University School of Medicine, New Orleans, La, USA
Search for more papers by this authorJuan J. L. Lertora MD, PhD
Sections of Nephrology and Clinical Pharmacology, Departments of Medicine, Pathology, and Pharmacology, Tulane University School of Medicine, New Orleans, La, USA
Search for more papers by this authorBurde L. Kamath PhD
Department of Pharmacokinetics, Xavier University College of Pharmacy, New Orleans, La, USA
Search for more papers by this authorAllan E. Rettie PhD
Department of Medicinal Chemistry, University of Washington School of Pharmacy, Seattle, Wash, USA
Search for more papers by this author
References
- 1Elston, A. C., Bayliss, M. K. and Park, G. R. (1993). Effect of renal failure on drug metabolism by the liver. Br J Anaesth 71: 282–290.
- 2Trager, W. F. (2000). Oral anticoagulants. In: R. H. Levy, K. E. Thummel, W. F. Trager, P. D. Hansten and M. Eichelbaum (Eds). Metabolic drug interactions. Lippincott Williams & Wilkins: Philadelphia. p. 403–414.
- 3Steward, D. J., Haining, R. L. and Henne, K. R. (1997). Genetic association between sensitivity to warfarin and expression of CYP2C9*3. Pharmacogenetics 7: 361–367.
- 4Henne, K. R., Gaedigk, A., Gupta, G., Leeder, J. S. and Rettie, A. E. (1998). Chiral phase analysis of warfarin enantiomers in patient plasma in relation to CYP2C9 genotype. J Chromatogr B Biomed Sci Appl 710: 143–148.
- 5Leblond, F., Geurin, C., Dmers, C., Pellerin, I., Gascon-Barre, M. and Pichette, V. (2001). Downregulation of hepatic cytochrome P450 in chronic renal failure. J Am Soc Nephrol 12: 326–332.
- 6Lee, C. R., Goldstein, J. A. and Pieper, J. A. (2002). Cytochrome P450 2C9 polymorphisms: a comprehensive review of the in-vitro and human data. Pharmacogenetics 12: 251–263.
- 7Tanaka, E. (1998). In vivo age-related changes in hepatic drug-oxidizing capacity in humans. J Clin Pharm Ther 23: 247–255.